---
title: '[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus highâ€‘dose
  long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3,
  well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an
  open-label, randomised, phase 3 study'
date: '2024-06-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38851203/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240609181219&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: There are currently no standard first-line treatment options
  for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic
  neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line
  [^(177)Lu]Lu-DOTA-TATE (^(177)Lu-Dotatate) ...'
disable_comments: true
---
BACKGROUND: There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [^(177)Lu]Lu-DOTA-TATE (^(177)Lu-Dotatate) ...